IP Watch on January 25 published GlaxoSmithKline’s position statement on the Anti-Counterfeiting Trade Agreement.  The company generally supports the agreement, as it “fully supports any efforts aimed at ensuring strong enforcement of IPRs.”  GSK would have preferred to have seen…